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Abstract
Background: Adhesions have important consequences for patients, surgeons, and health services. Peritoneal-
tissue injury can be prevented by using careful surgical techniques. A large number of antiadhesion products
have been used experimentally and clinically to prevent postoperative adhesions. Methods: The current author
reviewed the surgical literature published about epidemiology, pathogenesis, and various prevention strategies of
adhesion formation. Results: Meticulous surgery is essential to reduce unnecessary morbidity and mortality rates
from these untoward effects of surgery. Several preventive agents against postoperative peritoneal adhesions
have been investigated. Bioresorbable membranes are site-specific antiadhesion products but may be more
difficult to use laparoscopically. Liquids and gels have the advantage of more-widespread areas of action and
increased ease of use, particularly during laparoscopic operations. Effective pharmacologic agents that can
reduce release of proinflammatory cytokines or activate peritoneal fibrinolysis are under development. Their
results are encouraging but most of them are contradictory. Conclusions: Many modalities are being studied to
reduce this risk; despite initial promising results of different measures in postoperative adhesion prevention, none
of them have become standard applications. With the current state of knowledge, preclinical or clinical studies
are still necessary to evaluate the effectiveness of the several proposed prevention strategies for avoiding
postoperative peritoneal adhesions. ( J GYNECOL SURG 30:196)
Introduction
Adhesions are deposits of fibrous tissue that occurwithin the body’s cavities, such as the peritoneum,
pericardium, or pleura. In the majority of patients, adhesions
occur as a result of an injury to the lining membranes of the
cavities. Peritoneal injury usually occurs as a result of sur-
gery, peritonitis, or a combination of the two events.
Pelvic and abdominal adhesions have been associated
with significant morbidity, including infertility, chronic
pelvic pain, small-bowel obstruction, and difficulty with
surgical access or surgical complications in the future.
Adhesions result also in a large surgical workload and cost
to health care systems.1–3 In a large review from Scotland,
the total number of hospital admissions directly related to
adhesions in 1994 was similar to the number of hip re-
placements, coronary-artery bypasses, appendectomies, or
hemorrhoid operations.4
This current review of the literature discusses what is
known about the epidemiology, pathogenesis, and strategies
for preventing adhesion formation.
Incidence of Adhesions
It has been estimated that 90% of patients undergoing
major abdominal surgery and 55%–100% of women un-
dergoing pelvic surgery develop adhesions.5 It is generally
believed that some people are more prone to develop post-
operative adhesions than other people. Unfortunately, there
is no available marker to predict the occurrence, or the ex-
tent and severity, of adhesions preoperatively. In addition,
there are no available serum markers or imaging studies that
are generally considered to be able to predict the incidence,
severity, or extent of adhesions. Table 1 shows the inci-
dences of postsurgical adhesions.6–8
Historically, it has been difficult to analyzing the literature
on adhesion formation, because there is no single consistent
model of adhesion formation, and no standard and reliable
means of measuring this formation. A lack of standardiza-
tion has made comparison of studies difficult.
Pathogenesis of Adhesions
Histopathologic studies have demonstrated a clear se-
quence of events from injury to the formation of adhesions.
Peritoneal inflammation as result of an operative injury or
peritonitis leads to the formation of an inflammatory exudate
that contains strands of fibrin; vasoactive substances, such as
histamines and kinins, are released by the disruption of
stromal mast cells, increasing vascular permeability, which
contributes to the collection of a fibrin-rich exudate that
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covers the injured area. During surgery, the mesothelial
injury exposes a denuded and acellular surface that serves as
the nidus for wound healing and/or tissue–tissue adhesion.
This submesothelial damage and exposure of the matrix
occurs with simultaneous activation of the coagulation
cascade and deposition of fibrin at the site of injury. Under
normal conditions, this fibrinous exudate serves as a plat-
form for the progress of proper healing, but, under certain
circumstances, the deposited fibrin can, instead, serve as a
bridge between unrelated neighboring tissues. Within a short
period of time, the wound and its surrounding area are
invaded by inflammatory cells that migrate from the peri-
toneal vasculature or from the peritoneal fluid. The inflam-
matory exudate is initially composed of neutrophils; by 24
hours the predominant cell is the macrophage. Next, the
injured wound surface is evenly reperitonealized by the
combined effort of multiple foci of proliferating mesothelial
cells. Reperitonealization continues for 7–10 days, during
which time, the entire surface becomes covered by a con-
tinuous sheet of mesothelium. The presence of mesothelial
cells at the wound site corresponds to progressive wound
healing and/or fibrosis and the deposition of an extracellular
matrix (ECM) composed of fibronectin, hyaluronic acid,
various glycosaminoglycans, and proteoglycans. As the cells
realign, the temporary ECM molecules are replaced by
more-permanent proteins, such as collagens, while revas-
cularization continues.9
The balance between fibrin deposition and degradation is
critical in determining normal peritoneal healing or adhesion
formation. If fibrin is completely degraded, normal perito-
neal healing will occur. In contrast, if fibrin is not com-
pletely degraded, it will serve as a scaffold for fibroblast and
capillary deposits. This ECM is normally completely de-
graded by matrix metalloprotease, leading to normal heal-
ing. If this process is inhibited by tissue inhibitors of matrix
metalloprotease, peritoneal adhesions will form. In addition,
after elicitation of angiogenesis factors, such as vascular
endothelial growth factors (VEGFs), proliferation of endo-
thelial cells initiates the development of a vascular structure
within the adhesion tissue, which has been universally
claimed to be important in adhesion formation.10 The peri-
toneal plasminogen–activating activity (PAA) is reduced by
mechanical or chemical injury to the peritoneum, with the
release of proinflammatory cytokines that stimulate the
production of plasminogen-activator inhibitors 1 and 2
(PAI-1/2).11
Cofactors that contribute to adhesion formation
Ischemia. Ischemia has been proposed as the most im-
portant insult that leads to adhesion development. It has
been demonstrated that fibroblasts in adhesion tissues have a
different phenotype (myofibroblasts) than do the normal
peritoneal tissue fibroblasts. More importantly, it has been
shown that conversion of these cells from the normal
phenotype to the adhesion phenotype can be induced by
hypoxia.12 Compared with peritoneal fibroblasts, adhe-
sion fibroblasts have a significant increase in basal mRNA
levels of collagen I, fibronectin, matrix metalloprotei-
nase–1 (MMP-1), tissue inhibitor of metalloproteinase-1
(TIMP-1), transforming growth factor (TGF)–b1, cyclo-
oxygenase-2 (COX-2), and interleukin (IL)–10.12–16 Tis-
sue plasminogen activator (tPA) and PAI-1 are intracel-
lular enzymes found in the peritoneal mesenchymal cells.
These are involved in the intrinsic protective fibrinolytic
activity of fibroblasts. The tPA/PAI-1 ratio has been shown
to be 80% higher in normal peritoneal fibroblasts than in
adhesion fibroblasts. Under hypoxic conditions, this ratio
significantly decreases in normal and adhesion fibroblasts.13
MMPs and TIMPs are crucial proteolytic enzymes in the
extracellular matrix remodeling process of healing. Hypoxia
has been shown to inhibit MMP-1 and MMP-9 and augment
TIMP-1 expression. This decrease in the MMP/TIMP-1 ra-
tio during hypoxia may favor an increase in extracellular
matrix production, and a decrease in turnover and degra-
dation that may lead to tissue fibrosis and adhesion devel-
opment.14–16 COX-2 has been shown to have an important
role in the regulation of inflammation and angiogenesis. In
adhesion fibroblasts, the expression of COX-2 is signifi-
cantly increased, compared with that of normal fibroblasts.17
COX-2 inhibitors, such as celecoxib, tenoxicam, have been
reported to reduce postoperative adhesions through their
antiangiogenic, antiinflammatory, and antioxidant effects in
animal studies.18–19
Pneumoperitoneum. This is a cofactor in adhesion for-
mation, because adhesions have been shown in animal
models to increase with the duration of the pneumoper-
itoneum and with insufflation pressure.21,22 CO2 pneumo-
peritoneum induces adverse effects, such as hypercarbia,
acidosis, hypothermia, and desiccation23,24; and alters peri-
toneal fluid and the morphology of the mesothelial cells.25,26
Pelvic inflammatory disease and endometriosis. It is
recognized that pelvic inflammatory disease and endome-
triosis are additional potential causes of adhesions.27
Reactive oxygen species. Reactive oxygen species (ROS)
are produced in a hyperoxic environment and during the
ischemia/reperfusion process. ROS activity is injurious to
cells, which protect themselves with an antioxidant system
known as ROS scavengers. Recent data also point to a role
for ROS in adhesion formation, because the administration
of ROS scavengers has decreased adhesion formation in
several animal models.10 ROS activity increases during both
laparotomy and laparoscopy.
Tissue drying during surgery. This increases adhesions
formation; intentional drying of the tissues, is an other-
wise desirable procedure to aid the surgeon’s view of
the area but increases the risk of adhesion formation.
Laparotomy is more likely to produce adhesions than
laparoscopy.28,29
Table 1. Incidence of Postsurgical Adhesions6–8
Procedure %
Adhesiolysis 76%
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Types of intraperitoneal adhesions
Two types of adhesion formation are recognized and have
been classified are de novo adhesions (type 1) and reformed
adhesions (type 2). Table 2 shows the classification of
postoperative adhesion development.
Modes of Adhesion Prevention
A number of approaches are being developed to reduce
the incidence and severity of postoperative intra-abdominal
adhesions, with variable degrees of success. Some of these
approaches are site-specific to prevent localized adhesive
disease, while others work in a generalized fashion to pre-
vent adhesions throughout the peritoneal cavity.
Over the years, several measures—including microsurgi-
cal procedures, specialized equipment, unpowered gloves,
extensive irrigations, adhesion-reducing agents such as anti-
inflammatory agents, peritoneal instillates, and surgical
barriers—have been used to in attempts to prevent adhe-
sions. Among these measures, some barriers have proved
beneficial, but none of them have been found to prevent
adhesion development completely in all patients.
Current modes of adhesion prevention include:
 Careful surgical technique and minimally invasive
surgery whenever possible to reduce tissue injury
 Gelatinous/viscous liquids or bioresorbable membrane
barriers to separate damaged peritoneal surfaces
 Pharmacologic agents that reduce the peritoneal in-
flammatory reaction and cytokine release
 Products that stimulate peritoneal fibrinolytic activity
to enhance lysis of adhesion in the fibrinous stage.
Meticulous surgical technique
Meticulous surgical technique is an important part of
adhesion prevention. The principle is to minimize peritoneal
injury by careful handling of tissues, and precise alignment
and approximation of tissue planes. Avoidance of tissue
trauma, with gentle handling and prevention of thermal in-
jury, meticulous hemostasis, prevention of bacterial infec-
tion or fecal contamination, use of copious irrigation, and
avoidance of foreign objects intuitively make sense as in-
traoperative means of preventing postoperative adhesions.30
Whenever possible, all diseased and necrotic tissue should
be excised. Nonreactive suture material, such as polyglactin
(Vicryl), should be used, whereas using reactive material,
such as catgut, should be discouraged.
Access. The issue of whether laparoscopic surgery re-
sulted in fewer adhesions, compared to open laparotomy,
has been assessed. Diamond et al.31 found that the incidence
of de novo adhesion formation was lower when surgery was
performed laparoscopically, compared to laparotomy. In
addition, various advantages of this surgical approach have
made it more popular. These include: smaller skin-incision
size; early return of bowel function and ambulation; less
bleeding; and shorter hospital stay. As the peritoneal cavity
is normally sterile, warm, and wet, peritoneal injury during
laparoscopy may be minimized further by using filtered,
heated, and hydrated insufflating gas instead of the currently
used unconditioned dry gas.
In an attempt to prevent postoperative permanent fibrotic
adhesions, some surgeons have used a second-look laparos-
copy within 6 weeks following surgery to evaluate and lyse
soft intraperitoneal adhesions. The evidence supporting this
approach comes mainly from postoperative studies of uterine
myomectomy or pelvic adhesiolysis for infertility.32,33 Fur-
ther clinical studies and randomized trials are required before
this approach can be considered a proven method.
Peritoneal closure. Peritoneal closure is associated with
slightly longer operating and postoperative times, greater
postoperative pain, and more adhesions.34
Antiadhesion adjuvants
The pathogenesis of adhesion formation should direct
surgeons toward the best adhesion-preventing techniques.
While meticulous microsurgical technique should be main-
tained, there are new modalities that can aid in adhesion
prevention. A number of products—in liquid, gel, or mem-
brane forms—have been used clinically during abdominal
and pelvic operations to act as barriers to prevent adhesion
formation. The ideal product should be nonreactive but pro-
tect tissue at risk during the critical wound-healing period
before being resorbed and cleared. The product should remain
adherent to the target tissue and be easily applicable during
laparoscopic procedures performed on adhesiogenic organs,
such as adnexa, and remain active in the presence of blood.
No such product is currently available.
Mechanical barriers are available in two forms: (1) free-
floating abdominal instillates or (2) membrane barriers. Both
prevent adhesion formation by preventing tissue apposition
during the period of peritoneal repair and adhesion devel-
opment.
Mechanical barriers: Intraperitoneal solutions. There are
several abdominal instillates previously utilized in adhesion
prevention, which are currently no longer as crystalloids and
dextran 70.
Crystalloids—Cristalloids, such as normal saline and
Ringer’s lactate, were used to produce a hydroflotation
Table 2. Classification of Postoperative Adhesion
Development
Type # Descriptions
Type 1 De novo adhesion formation
A. No operative procedure at site of adhesion
formation
B. Operative procedure performed at site of
adhesion formation
Type 2 Adhesion reformation; redevelopment of ad-
hesions at sites at which adhesiolysis was
performed
A. No operative procedure at site of adhesion
reformation (other than adhesiolysis)
B. Operative procedure performed at site of
adhesion reformation (in addition to
adhesiolysis)
Source: Diamond MP, Nezhat F. Adhesions after resection of
ovarian endometriomas. Fertil Steril 1993;59:934.
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effect by instilling 500mL to 3L of fluid into the peritoneal
cavity at the end of surgery. Irrespective of the volume in-
stilled, the absorption rate by the peritoneum ensured that all
the fluids were reabsorbed into the vascular circulation in
24–48 hours, but this was too short an interval to prevent
adhesion formation.35
Dextran—Dextran is a water-soluble glucose polymer
originally used as a plasma expander. Hyperosmolar solu-
tions as Hyskon (32% dextran in 10% dextrose solution),
were absorbed in 5–7 days and worked by mechanical
separation of serosal membranes through hydroflotation and
producing a ‘‘siliconizing’’ effect.35 Dextran has also an
antithrombotic activity that retards adherence of blood clots
and deposition of fibrin matrix. Serious side-effects have
been reported that include coagulopathy, anaphylaxis, and
ascites. Dextran has not been approved for use as an anti-
adhesive agent.
Hydrogel—Sprayable hydrogel, SprayGel (Confluent
Surgical, Waltham, MA), is a gel-based adhesion barrier. It
is a hydrophilic polyethylene glycol barrier formed by
combining two streams of liquid polymers, delivered via a
catheter to the target tissue. When combined, the two
streams produce a bright-blue solid polymer within minutes.
SprayGel hydrogel can be applied during laparoscopy eas-
ily. After 5 days, the hydrogel layer is reabsorbed and
undergoes renal clearance. In a European, multicenter ran-
domized study, Mettler et al.,36 evaluated 66 women who
underwent myomectomy with or without SprayGel appli-
cation. When compared with initial surgery, the mean ad-
hesion tenacity score of adhesion seen at a second-look
laparoscopy was 64.7% lower in patients receiving the ad-
hesion barrier than in control patients (0.6 versus 1.7).
Compared with initial surgery, in the adhesion-barrier re-
cipients versus the controls, respectively, the mean adhesion
extent scores at second-look laparoscopy were 4.5 versus
7.2 cm2, and the mean adhesion incidence scores were 0.64
versus 1.22. There were no adverse effects attributed to the
adhesion barrier.
Icodextrin solution—A relatively new agent, an icodex-
trin Solution, Adept (Baxter, Deerfield, IL), has been ap-
proved by the Food and Drug Administration to be used in
laparoscopy and holds promising results as an adhesion-
preventing agent. It is a 4% icodextrin solution that is sterile
and clear. The solution is a colorless-to pale-yellow fluid
that prevents adhesion formation by acting as a physical
separation of the peritoneal surfaces during the early phases
of natural healing. The presence of weight-molecular spe-
cies of icodextrin, which are not easily absorbed, justifies its
ability to maintain a reservoir of fluid in the peritoneal
cavity via colloidal osmosis. In 2007, in the largest pro-
spective randomized double-blinded study to date, icodex-
trin 4% has been shown to be safe and to result in a
significant reduction of incidence, severity, and extent of
adhesions. In addition, the study showed that this solution
prevents deterioration of preexisting adhesions.37
Mechanical barriers: Membrane form. There has been
particular interest in recent years in the use of absorbable or
nonabsorbable membranes that are applied topically to
separate traumatized peritoneal surfaces and prevent adhe-
sion formation or reformation. The critical period for the
action of these compounds is the first 5–7 days following
injury. Many different mechanical barriers have been tried,
but they are generally inadequate, because they interfere
with blood supply or produce foreign-body reactions. Unlike
their liquid counterparts, membrane forms prevent adhe-
sions only in their areas of application. The membranes
most commonly used are Interceed ( Johnson & Johnson
Medical, Summevile, NJ), Seprafilm (Genzym Corpora-
tion, Cambridge, MA), and Gore-Tex Surgical Membrane
(W.L. Gore & Associates, Inc., Flagstaff, AZ).
Oxidized regenerated cellulose—Interceed is gelatinous
material, made of oxidized regenerated cellulose, which is
absorbed slowly from the peritoneal cavity over 28 days. A
meta-analysis of 11 relevant randomized controlled trials
(RCTs) has shown that the barrier was safe and was asso-
ciated with a reduced incidence of pelvic adhesion for-
mation, both new formation and reformation, following
laparoscopic surgery38 The benefit of Interceed was also
supported by multicenter studies in Japan (laparotomy) and
Germany (laparoscopic surgery)39,40; its use was associated
with a reduced incidence of pelvic-adhesion formation fol-
lowing laparoscopy and laparotomy. Interceed is available
in sheets measuring 1.5 · 2 inches or 3 · 4 inches. After
application, it becomes a viscous gel that is completely
absorbed in 4 weeks. The smaller size is appropriate for
laparoscopic placement. This product is a procoagulant and
can induce fibrin deposition in the presence of blood within
the peritoneal cavity, so complete hemostasis is required
before topical application. It is important to apply the
product in single layers, interposed between adjacent ana-
tomical structures at risk for adhesion. It is contraindicated
for use in the presence of ongoing infection in the pelvic or
abdominal cavities.
Expanded polytetrafluoroethylene—Expanded polytetra-
fluorethylene membrane (Gore-Tex) is a nonabsorbable and
nonreactive membrane that has been used to repair both the
pericardium and peritoneum. This product’s effectiveness
for preventing localized adhesion formation has been shown
in two large prospective multicenter studies reported by the
Surgical Membrane Study Group and the Myomectomy
Adhesion Study Group.41,42 The disadvantages of this product
are the permanent presence of a foreign body in the peritoneal
cavity and the requirement for suture fixation of the mem-
brane, which can be difficult during laparoscopy. A Cochrane
Database review compared the use of Gore-Tex versus In-
terceed and controls in three studies on woman, following
various gynecologic procedures via laparoscopy and lapa-
rotomy. Gore-Tex was found to be more effective than In-
terceed or no barrier for preventing adhesion formation.
This superiority was confirmed with respect to size of ad-
hesion area, tenacity, and vascularity, with significant im-
provement in total adhesion score. However, this product’s
usefulness is limited because it must be sutured in place and
removed during a subsequent surgery. As a result of this, the
use of this barrier has fallen out of favor in recent years.
Nevertheless, studies have shown that removal of Gore-Tex
at early second-look laparoscopy (11 days after myo-
mectomy) was not associated with adhesions.37
Seprafilm—Seprafilm is a sterile translucent membrane
comprised of sodium hyaluronate and carboxymethylcellu-
lose, which temporarily separates potentially adherent sur-
faces, turning into a gel within 24 hours and covering
serosal surfaces for 7 days. The product is excreted from the
ADHESION PREVENTION IN LAPAROSCOPIC SURGERY 199
body in*28 days, and its use is not restricted in presence of
blood. However, the product progressively loses its initial
adherence and can migrate for some distance, thereby
leaving a wound unprotected. It is difficult to manipulate
during laparoscopy because of handling limitations; there
are off-label reports of rolling Seprafilm in a wrap or making
a slurry to make it applicable in laparoscopy. Conflicting
studies exist regarding the product’s effectiveness: The
benefit of Seprafilm for reducing localized intra-abdominal
adhesion formation in gynecologic surgery was demon-
strated in two randomized controlled clinical trials, espe-
cially following myomectomies.43,44 However, Vrijland
et al., found that Seprafilm decreased the severity but not the
incidence of adhesions in a prospective study of patients
undergoing a Hartmann procedure for diverticulitis or an
obstructed rectosigmoid.45
Oxiplex—Oxiplex (Frizomed, Inc. San Luis Obispo,
CA) is another promising membrane barrier undergoing
investigation for gynecologic use. The product is specifi-
cally formulated for laparoscopic applications. It consists
of a viscoelastic gel, composed of polyethylene oxide and
carboxymethylcellulose, and is cleared by phagocytosis
within 96 hours. It is a biocompatible resorbable film, with
good handling properties and tissue adherence. The product
is easily applied laparoscopically through a 5-mm trocar.
The presence of blood at a membrane–tissue interface, al-
though not studied directly, did not seem to affect the re-
sults. Oxiplex has been well-studied in rabbits and found to
be promising for reducing postoperative adhesions.46–48 In
another study, 49 patients had laparoscopic gynecologic
surgery: 24 of 49 patients had surgery with viscoelastic
(Oxiplex) gel placement on their adnexal area and the re-
maining 25 received only surgery. Treated adnexa had a
decrease in American Fertility Society (AFS) score (11.9–
9.1); in contrast, control adnexa had an increase in AFS
score (8.8–15.8). This difference in second-look AFS score
(42% reduction) was significant.49
Antiadhesion pharmacologic agents
Systemically and orally specific inhibitors of adhesiogenesis
are the goals of pharmaceutical research in this area. An in-
creasing number of pharmacologic agents have been used to
reduce the peritoneal inflammatory response to injury. These
agents include corticosteroids, histamine antagonists, antioxi-
dants, and calcium channel-blocking agents. The benefit of
many of these agents has been demonstrated in animal
studies, although proof of their efficacy in human studies is
sparse.50,51 Many of these agents may be used systemically or
topically, but the maintenance of a localized effect within the
peritoneal cavity for a sufficient length of time to prevent
adhesion formation has been a persistent problem. Other
studies have been performed to manipulate coagulation
mechanisms or to stimulate peritoneal fibrinolytic activity,
with some success. Anticoagulation with warfarin or heparin
is effective for preventing adhesion formation but carries a
Table 3. Antiadhesion Products
Products Mode of action Disavantages Notes
Clinical
effectiveness Year





Dextran Hydroflotation of organs Coagulopathy, anaphylaxis,
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Absorption 4w + 2008
Expanded
polytetrafluoroethylene
Mechanical barrier Permanent foreign body;
difficult to use in
laparoscopy; site-specific





Absorption 4w + 1996
Oxiplex Bioresorbable adherent
film













h, hours; d, days; w, weeks; AAA, antiadhesion agent; NSAIDs, nonsteroidal anti-inflammatory drugs.
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risk of intraperitoneal hemorrhage and is not in clinical use.
There is some experimental evidence of localized reduction
in adhesion formation with the use of some fibrinolytic en-
zymes such as streptokinase, urokinase, plasmin, and t-PA,
especially when incorporated into a slow-release gel. Despite
these results, there is little known about the pharmacokinetics
of intraperitoneal administration and the proper dosage and
length or treatment necessary.
Nonsteroidal anti-inflammatory drugs (local and system-
ic) have been studied for their possible antiadhesion bene-
fits, by modifying arachidonic-acid metabolism and altering
cyclo-oxygenase activities. Their clinical effectiveness is
questionable because of inadequate concentrations at de-
vascularized sites of surgical trauma.52
Progesterone has been used for preventing adhesion for-
mation. This agent has shown to decrease the incidence of
postoperative adhesions in animal models; this hypothesis,
however, has never been proven in humans.53
Antibiotics are used for prophylaxis against postoperative
infections and hence the inflammatory response; studies
show that peritoneal irrigation with antibiotic solutions does
not reduce adhesion formation.54 Table 3 summarizes in-
formation about some antiadhesions products.
Conclusions
Adhesions have important consequences for patients,
surgeons. and health services. Operative injury and/or
peritonitis leads to peritoneal inflammation and then to ad-
hesions. Management of these adhesion-related clinical
problems results in a large surgical workload and cost to the
National Health Service, which emphasizes the importance
of prevention. Many modalities are being studied to reduce
this risk; despite initial promising results of different mea-
sures for postoperative adhesion prevention, none of them
have become standard applications.
Peritoneal-tissue injury can be prevented by using a
careful surgical technique. There is increasing evidence that
use of laparoscopic procedures reduces the incidence of de
novo and incisional adhesions. Knowledge of the risk fac-
tors, use of a good surgical technique to minimize tissue
trauma, and use of proper instruments and ancillary tech-
nologies has been shown to decrease complications and the
severity of adhesion formation.
A large number of antiadhesion products have been used
experimentally and clinically to prevent postoperative ad-
hesions. Bioresorbable membranes are site-specific anti-
adhesion products but may be more difficult to use
laparoscopically. Liquids and gels have the advantages of
more-widespread areas of action and increased ease of use,
particularly during laparoscopic operations. Effective phar-
macologic agents that can reduce release of proin-
flammatory cytokines or activate peritoneal fibrinolysis are
under development. One key challenge is that these physical
agents may reduce adhesions where they are placed but do
not prevent adhesions developing elsewhere in the abdomen.
The ideal adhesion-reduction agent should be easy to use for
all type of surgical procedures and be capable of reducing
adhesion formation at the operation sites and throughout the
peritoneum. Box 1 summarizes the level of evidence for the
various approaches.55 Further advances are likely to occur
over the next few years.
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